Compare Danaher Corporation (DHR) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs UiPath Inc — how do they compare? Danaher Corporation trades at $199.47 (market cap $141.67B), while UiPath Inc trades at $11.98 (market cap $6.14B). The key difference: Danaher Corporation is far larger — about 23.1× UiPath Inc's market cap, and Danaher Corporation pays a 0.8% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| DHR | PATH | |
|---|---|---|
Market Cap | $141.67B | $6.14B |
Sector | Health | Technology |
52-Week High | $242.05 | $19.29 |
52-Week Low | $161.91 | $9.38 |
Enterprise Value | $154.45B | $4.92B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
UiPath (PATH) trades at $11.85, up 1.46% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent earnings show mixed results with Q1 2026 missing expectations but strong gross margins of 83.01% highlight operational efficiency. Analyst consensus price target sits at $13.33 with 25% buy ratings.
PATH presents a compelling turnaround story with accelerating revenue growth and path to profitability. Key opportunities include agentic AI adoption through Maestro platform and expanding enterprise automation. Risks include execution challenges in AI monetization, competitive pressures, and the stock's premium valuation multiples requiring sustained growth delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
